Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Zofran, Zofran Preservative Free, Zofran And Dextrose In Plastic Container. Every FDA application for this active ingredient: 4 branded and 68 generic.
As of Nov 15, 2026, FDA lists 72 applications for Ondansetron Hydrochloride (sold as Zofran, Zofran Preservative Free, Zofran And Dextrose In Plastic Container), first approved Jan 4, 1991, with 9 new uses approved and 0 published complete response letters.
First approved: Jan 4, 1991
Applications: 72
New uses approved: 9
Complete response letters: 0
Medicare spending, 2025: $155K
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Ondansetron HCL (J2405)
Part B
$154K
-16%
52,173
Ondansetron HCL (Q0162)
Part B
$1K
+21%
216
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
ONDANSETRON 4 MG/5 ML SOLUTION: $0.288 per MLGeneric · 0% in a year
ONDANSETRON 4 MG/5 ML SOLUTION CUP: $0.288 per MLGeneric · 0% in a year
ONDANSETRON 40 MG/20 ML VIAL: $0.193 per MLGeneric · +12% in a year
ONDANSETRON HCL 4 MG TABLET: $0.058 per unitGeneric · -16% in a year
ONDANSETRON HCL 4 MG/2 ML VIAL: $0.177 per MLGeneric · -14% in a year
ONDANSETRON HCL 8 MG TABLET: $0.077 per unitGeneric · -19% in a year
ONDANSETRON ODT 4 MG TABLET: $0.123 per unitGeneric · -22% in a year
ONDANSETRON ODT 8 MG TABLET: $0.180 per unitGeneric · +1% in a year
OndansetronA drug with a new indication and a new dosage for the treatment of digestive symptoms (nausea and vomiting) after surgery. · Maruishi Pharmaceutical Co., Ltd. · Feb 25, 2022
Clinical Trials
100 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Sandoz
Glaxosmithkline
Teva
Hikma
Fresenius Kabi USA
Sun Pharm Inds Ltd
Apotex
Aurobindo Pharma
Eugia Pharma
Baxter Hlthcare Corp
Accord Hlthcare